Skip to main content

Table 3 Correlation between clinicopathological features and PD-1, PD-L1, and PD-L2 expression in 61 triple-negative and 45 HER2-positive breast cancers

From: Prediction of treatment responses to neoadjuvant chemotherapy in triple-negative breast cancer by analysis of immune checkpoint protein expression

Parameters PD-1 PD-L1 PD-L2
Positive (n = 18) Negative (n = 43) p value Positive (n = 24) Negative (n = 37) p value Positive (n = 20) Negative (n = 41) p value
TNBC (n = 61)
 Age at operation
  ≤ 56 4 (22.2%) 24 (55.8%) 0.016 10 (41.7%) 18 (48.6%) 0.593 12 (60.0%) 16 (39.0%) 0.123
  > 56 14 (77.8%) 19 (44.2%) 14 (58.3%) 19 (51.4%) 8 (40.0%) 25 (61.0%)
 Menopause
  Negative 4 (22.2%) 18 (41.9%) 0.121 9 (37.5%) 13 (35.1%) 0.851 8 (40.0%) 14 (34.1%) 0.655
  Positive 14 (77.8%) 25 (58.1%) 15 (62.5%) 24 (64.9%) 12 (60.0%) 27 (65.9%)
 Tumor size (cm)
  ≤ 2 3 (16.7%) 4 (9.3%) 0.337 3 (12.5%) 4 (10.8%) 0.573 3 (15.0%) 4 (9.8%) 0.416
  > 2 15 (83.3%) 39 (90.7%) 21 (87.5%) 33 (89.2%) 17 (85.0%) 37 (90.2%)
 Lymph node status
  Negative 3 (16.7%) 8 (18.6%) 0.586 5 (20.8%) 6 (16.2%) 0.647 3 (15.0%) 8 (19.5%) 0.481
  Positive 15 (83.3%) 35 (81.4%) 19 (79.2%) 31 (83.8%) 17 (85.0%) 33 (80.5%)
 Nuclear grade
  1, 2 13 (72.2%) 31 (72.1%) 0.992 19 (79.2%) 25 (67.6%) 0.324 14 (70.0%) 30 (73.2%) 0.795
  3 5 (27.8%) 12 (27.9%) 5 (20.8%) 12 (32.4%) 6 (30.0%) 11 (26.8%)
 Ki67
  ≤ 14% 6 (33.3%) 12 (27.9%) 0.672 12 (50.0%) 6 (16.2%) 0.005 6 (30.0%) 12 (29.3%) 0.953
  > 14% 12 (66.7%) 31 (72.1%) 12 (50.0%) 31 (83.8%) 14 (70.0%) 29 (70.7%)
 Pathological response
  pCR 3 (16.7%) 25 (58.1%) 0.003 3 (12.5%) 25 (67.6%) < 0.001 10 (50.0%) 18 (43.9%) 0.654
  Non-pCR 15 (83.3%) 18 (41.9%) 21 (87.5%) 12 (32.4%) 10 (50.0%) 23 (56.1%)
 PD-1
  Negative Not determined Not determined   9 (37.5%) 34 (91.9%) < 0.001 12 (60.0%) 31 (75.6%) 0.210
  Positive 15 (62.5%) 3 (8.1%) 8 (40.0%) 10 (24.4%)
 PD-L1
  Negative 3 (16.7%) 34 (48.4%) < 0.001 Not determined Not determined   10 (50.0%) 27 (65.9%) 0.234
  Positive 15 (83.3%) 9 (51.6%)   10 (50.0%) 14 (34.1%)
 PD-L2
  Negative 10 (55.6%) 31 (79.1%) 0.210 14 (58.3%) 27 (73.0%) 0.234 Not determined Not determined  
  Positive 8 (44.4%) 12 (20.9%) 10 (41.7%) 10 (27.0%)
Parameters PD-1 PD-L1 PD-L2
Positive (n = 3) Negative (n = 42) p value Positive (n = 4) Negative (n = 41) p value Positive (n = 16) Negative (n = 29) p value
HER2+BC (n = 45)
 Age at operation
  ≤ 56 0 (0.0%) 20 (47.6%) 0.162 1 (25.0%) 19 (46.3%) 0.394 6 (37.5%) 14 (48.3%) 0.486
  > 56 3 (100.0%) 22 (52.4%) 3 (75.0%) 22 (53.7%) 10 (62.5%) 15 (51.7%)
 Menopause
  Negative 0 (0.0%) 18 (42.9%) 0.206 1 (25.0%) 17 (41.5%) 0.471 6 (37.5%) 12 (41.4%) 0.799
  Positive 3 (100.0%) 24 (57.1%) 3 (75.0%) 24 (58.5%) 10 (62.5%) 17 (58.6%)
 Tumor size (cm)
  ≤ 2 1 (33.3%) 5 (11.9%) 0.356 1 (25.0%) 5 (12.2%) 0.448 4 (25.0%) 2 (6.9%) 0.107
  > 2 2 (66.7%) 37 (88.1%) 3 (75.0%) 36 (87.8%) 12 (75.0%) 27 (93.1%)
 Lymph node status
  Negative 1 (33.3%) 15 (35.7%) 0.715 2 (50.0%) 14 (34.2%) 0.448 5 (31.3%) 11 (37.9%) 0.455
  Positive 2 (66.7%) 27 (64.3%) 2 (50.0%) 27 (65.8%) 11 (68.7%) 18 (62.1%)
 Nuclear grade
  1, 2 2 (66.7%) 33 (78.6%) 0.539 2 (50.0%) 33 (80.5%) 0.209 12 (75.0%) 23 (79.3%) 0.508
  3 1 (33.3%) 9 (21.4%) 2 (50.0%) 8 (19.5%) 4 (25.0%) 6 (20.7%)
 Ki67
  ≤ 14% 1 (33.3%) 23 (54.8%) 0.449 1 (25.0%) 23 (56.1%) 0.254 7 (43.8%) 17 (58.6%) 0.338
  > 14% 2 (66.7%) 19 (45.2%) 3 (75.0%) 18 (43.9%) 9 (56.2%) 12 (41.4%)
 Pathological response
  pCR 0 (0.0%) 18 (42.9%) 0.206 1 (25.0%) 17 (41.5%) 0.471 11 (62.5%) 7 (24.1%) 0.005
  Non-pCR 3 (100.0%) 24 (57.1%) 3 (75.0%) 24 (58.5%) 5 (37.5%) 22 (75.9%)
 PD-1
  Negative Not determined Not determined   1 (25.0%) 41 (100.0%) < 0.001 13 (81.3%) 29 (100.0%) 0.039
  Positive 3 (75.0%) 0 (0.0%) 3 (18.7%) 0 (0.0%)
 PD-L1
  Negative 0 (0.0%) 41 (97.6%) < 0.001 Not determined Not determined   12 (75.0%) 29 (100.0%) 0.012
  Positive 3 (100.0%) 1 (2.4%) 4 (25.0%) 0 (0.0%)
 PD-L2
  Negative 0 (0.0%) 29 (69.0%) 0.039 0 (0.0%) 29 (70.7%) 0.012 Not determined Not determined  
  Positive 3 (100.0%) 13 (31.0%) 4 (100.0%) 12 (29.3%)
  1. TNBC triple-negative breast cancer, HER2 human epidermal growth factor receptor 2, BC breast cancer, pCR pathological complete response, PD-1 programmed cell death-1, PD-L programmed cell death-ligand